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Purpose: To investigate the expression of MUC16 protein in tears and conjunctival cell membranes and MUC16 mRNA
in conjunctival cells of Sjogren’s syndrome (SS), keratoconjunctivitus sicca (KCS) and non-dry eyed (NDE) subjects.
The relationship of tear flow and soluble MUC16 concentration was also measured.
Methods: Seventy-six subjects were recruited for this study: 25 SS (confirmed via American-European Consensus Criteria
2002), 25 KCS (confirmed by symptoms and Schirmer scores ≤10 mm) and 26 NDE. Tear flow was measured by the
Schirmer test without anesthesia for 5 min. Tears were collected using an eye-wash technique. Protein and mRNA were
isolated from conjunctival epithelial cells collected via impression cytology. Soluble and membrane bound MUC16 were
quantified via western blotting and MUC16 mRNA was quantified by real time qPCR.
Results: The SS group demonstrated significantly higher concentrations of soluble MUC16 (7.28 [SS]±3.97 versus 3.35
[KCS]±4.54 [p=0.004] and versus 1.61 [NDE]±1.22 [p<0.001]) and MUC16 mRNA (4.66 [SS]±5.06 versus 1.84 [KCS]
±2.26 [p=0.01] and 1.52 [NDE]±1.04 [p=0.003]) compared to both KCS and NDE groups, respectively. No differences
in soluble MUC16 or MUC16 mRNA were found between the KCS and NDE groups. Membrane bound MUC16 was
similar in all three groups. No significant correlation was found between mean Schirmer values and any measure of MUC16
expression.
Conclusions: These results demonstrate that SS subjects display a significant increase in both soluble MUC16 and MUC16
mRNA concentrations compared to other forms of aqueous deficient dry eye and non dry-eyed individuals. There was no
correlation between tear flow and soluble MUC16 concentration.
Mucins constitute an important part of the preocular tear
film and ocular surface. Our current understanding is that the
tear film is best described as a mucin/aqueous gel decreasing
in density toward the lipid layer [1,2]. Mucins are believed to
play a key role in the retention of water and other tear fluid
components on the ocular surface, hence maintaining both
lubricity of the ocular surface and a healthy epithelial barrier
[3,4]. Early concepts of ocular mucins described goblet cells
as the sole origin of secretion [5]. However, numerous studies
have now shown multiple species of mucins are also derived
from the ocular surface epithelium [6-10].
To date, 20 human mucin genes have been completely or
partially sequenced. They have been named and numbered
chronologically  with  their  discovery:  MUC1,  MUC2,
MUC3A,  MUC3B,  MUC4,  MUC5AC,  MUC5B,  MUC6–9,
MUC11–13, MUC15–17, and MUC20 [11-19].
Based on the presence of common structures within their
amino acid sequences, they have been grouped together into
three broad groups [6,11,14-20]:
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1. Gel-forming mucins from goblet cells of various
epithelia: MUC2, MUC5AC, MUC5B, MUC6, and
MUC19
2. Soluble mucins: MUC7 and MUC9
3. Membrane-associated  mucins:  MUC1,
MUC3A,  MUC3B,  MUC4,  MUC11,  MUC12,
MUC13, MUC15, MUC16, MUC17, and MUC20.
Both secreted (MUC2, MUC5AC, MUC5B, and MUC7)
and membrane bound (MUC1, MUC4, and MUC16) mucin
forms have been reported to be expressed by ocular surface
epithelia [6,21,22]. Of the mucins identified on the ocular
surface,  two  soluble  (MUC2  and  MUC5AC)  and  three
membrane-bound (MUC1, MUC4, and MUC16) forms are
considered “critical” for the maintenance of a “normal” tear
film  [21].  MUC2  and  MUC5B  are  present  in  very  low
quantities [21-23].
Recent research has demonstrated that alternative soluble
forms [23-27] of MUC1 [24] and MUC16 exist, as has been
illustrated  by  Spurr-Michaud  et  al.  [23],  who  described
soluble MUC16 in the tears. The alternative forms of MUC1
and MUC16 lack the cytoplasmic tail portion of the protein
and thus are secreted or shed into the tear film, as opposed to
being anchored on epithelial cell membranes. Whether these
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2547soluble species are present in all tear samples or are linked to
ocular surface pathology is not yet clear. Also unclear is the
functions  attributed  to  these  alternative,  soluble  forms  of
MUC1 and MUC16.
The  functions  of  MUC16  are  slowly  becoming
understood. Blalock et al. [22] using immortalized corneal-
limbal epithelial cells (HCLE), suggested that MUC16 forms
a protective barrier on these cells, without which there is rose
bengal dye penetrance and adherence of S. aureus. They locate
MUC 16 on the tips of the HCLE cell surface and suggested
that the cytoplasmic tail binds to the actin cytoskeleton. No
such work has been done with human conjunctival cells.
Although alterations in mucin expression and/or mucin
glycosylation have been implicated in the pathophysiology of
dry eye, only a limited number of studies addressing these
issues  have  been  conducted.  The  recent  DEWS  report
eliminated  the  separate  classification  of  primary  mucin
deficient dry eye [28], with their classification supporting both
aqueous-deficient (AD) and evaporative (E) dry eye groups.
Within the AD dry eye group, two major subclasses exist,
namely Sjogren’s Syndrome (SS) dry eye and Non-SS dry
eye.
The role of mucins in dry eye disease has mainly focused
on MUC5AC, and it is generally assumed that the expression
of MUC5AC is reduced in dry eyed subjects [29]. Recently,
attention has also been placed on membrane spanning mucins
and their potential role in dry eye [22,30]. Danjo et al. [30],
have reported that the conjunctival epithelial cell distribution
of H185 (MUC16) is altered in non-SS dry eye subjects.
It is the membrane spanning mucin MUC16 that is the
subject of this paper. Specifically, we sought to characterize
the expression of MUC16 in Sjogren’s syndrome dry eye as
compared with aqueous deficient (KCS) dry eye and non dry-
eyed (NDE) controls, to gain further insight into the role that
MUC16 may play in dry eye disease. In addition, we examined
the relationship between soluble MUC16 expression and tear
flow as measured by Schirmer testing.
METHODS
Study Design: Prior to the start of this study, ethics approval
was  attained  from  the  Office  of  Research  Ethics  at  the
University of Waterloo and University of Toronto and all
procedures adhered to the Declaration of Helsinki. A total of
76 subjects (26 non dry-eyed controls [NDE], 25 Sjogrens
subjects  [SS],  and  25  non-Sjogrens  keratoconjunctivitis
[KCS]) were enrolled in this study. All participants underwent
a clinical evaluation visit to determine entry eligibility before
a second visit in which ocular samples were collected.
All SS participants had been diagnosed with primary SS
at the Sjogren’s Syndrome Clinic of the Toronto Western
Hospital, using the American-European consensus criteria of
2002 [31]. Thus, each of these subjects had 3 or more of the
following criteria: symptoms and signs of dry eye and dry
mouth and each had one of: a positive minor salivary gland
biopsy or the presence of SS specific antibodies Ro and/or La
in the serum. Recruitment of these patients was achieved
through telephone calls from the database of that clinic. No
further preliminary screening was performed on this group as
all had confirmed Sjogren’s Syndrome.
The KCS and NDE subjects were recruited through the
SS clinic and a private practice. Participants first answered the
question “If you have dry eyes, have they been dry for at least
3 months”? Participants that answered “yes,” were asked to
rate their dryness on a visual analog scale used routinely in
the SS clinic. The horizontal line of the scale was marked from
0 to 10. At the 0 point the words “not dry at all” were written
and at the 10 “as dry as the desert” was written. If they rated
their dryness as greater than or equal to 6 out of 10 on the
visual analog scale and the Schirmer 1 test score was less than
or equal to 10 mm in 5 min in at least one eye, they were
classified as KCS. Non-dry eye subjects (NDE) were enrolled
if they stated that they did not have dry eyes, ranked their
dryness as 0 on the visual analog scale and had Schirmer I
scores of greater than 10 mm in both eyes. All subjects were
free from allergy or other ocular surface diseases and all were
on maximum therapy for blepharitis, if that condition had been
previously diagnosed. Thus, where appropriate, they were
using lid scrubs and hot soaks but were not using topical
antibiotics or topical anti-inflammatories. Pre-screening for
KCS and NDE subjects was performed within two months of
the actual clinic visit for collection of tears and impression
cytology specimens. Participants were required to confirm
that their dry eye status had not changed at the collection visit
to be included in the study.
Reagents  and  Materials:  Agarose  was  purchased  from
Cambrex  Bio  Science  (Rockland,  ME).  Gel  buffer,  tank
buffer, vacuum blotter, nitrocellulose membrane and, blotting
paper  were  purchased  from  BioRad  (Mississauga,  ON,
Canada).  Glycerol  and  20X  SSC  transfer  buffer  were
purchased from VWR (Mississauga, On, Canada). Molecular
weight standards (Himark™) were purchased from Invitrogen
(Carlsbad, CA). ECL-Plus™ lits were purchased from GE
Healthcare (Baie d”Urfe, QC, Canada). DC Protein Assay
Kits® were purchased from BioRad. Monoclonal mouse anti-
human  MUC16  antibody  (OC125)  was  purchased  from
DAKO (Glostrup, Denmark) and goat anti-mouse IgG-HRP
from  Santa  Cruz  Biotechnology  Inc.  (Santa  Cruz,  CA).
Millipore™  Membrane  Filters  were  purchased  from
Millipore™ (Billerica, MA)
The Schirmer I test: The Schirmer I test was performed using
pre-packaged,  sterile  paper  strips  (Schirmer  Tear  Test
Strips®; Alcon, Fort Worth, TX), without anesthesia. The
rounded bulb end of the strip was folded at the notch and then
inserted into the lower fornix, one third of the distance from
the lateral canthus of the lower lid. Once both strips were in
place, the subject was asked to close their eyes. After 5 min
the strips were removed and the wet portion measured in mm.
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wash method as described elsewhere [29]. Briefly, 60 µl of
sterile,  physiologic  saline  (0.9%  NaCl;  Minims;  Chauvin
Pharmaceuticals Ltd, Romford, Essex, UK) was applied to the
superior bulbar region of the unanaesthetized ocular surface
(right  eye)  using  a  sterile  micropipette.  Participants  were
asked to rotate their eyes without blinking (lids were still held
open), to mix the tear fluid. Tear washes were collected from
the inferior fornix of each eye using the sterile micropipette.
The same procedure was repeated with the left eye. Both eye
washes were pooled together, vortexed briefly, then placed on
dry ice until transfer to −80 °C for storage.
Conjunctival  impression  cytology  (CIC):  Conjunctival
epithelial cells were collected via impression cytology from
each eye using sterile Millipore, MF membranes, (pore size
0.45  μM).  Two  drops  of  a  topical  anesthetic  (Alcaine®,
Alcon), dosed 60 s apart, were applied to the right eye. Fifteen
seconds after the second drop of anesthetic, the subject was
instructed  to  hold  gaze  down  to  expose  the  superior
conjunctiva. The investigator held the upper lid up to fully
expose the superior conjunctiva. One piece of filter paper was
placed on the superior region of the conjunctiva for five to
seven seconds then removed with blunt forceps and placed in
a sterile pre-labeled 2 ml capped polypropylene centrifuge
tube containing 1 ml of RLT® RNA Isolation Buffer (Qiagen,
Germantown, MD) containing 0.01% β-mercaptoethanol. The
same procedure of impression cytology then took place on the
temporal conjunctiva and the filter paper was placed in the
same tube as the superior sample. Anaesthesia and impression
cytology of the left eye then took place as described for the
right eye, with the exception that the two filter papers were
placed  in  an  empty  sterile  2  ml  capped  polypropylene
centrifuge tube, such that protein extraction could take place.
All  samples  were  immediately  placed  on  dry  ice,  then
transferred to −80 °C for storage until processing.
Protein  isolation  from  CIC  samples:  Impression  cytology
filter papers that were collected from the left eyes of subjects
were used to isolate total protein. Filter papers were placed
cell side up on small glass plates and 5 µl of extraction buffer
(2% SDS; 1X Complete™ protease inhibitor cocktail [Roche,
Mannheim, Germany]) was placed on each. Using a steel
scalpel blade, each membrane was cut into small pieces, which
were placed in 600 μl capped polypropylene centrifuge tubes
and covered with an additional 50 µl of extraction buffer.
Tubes were vortexed, then heated at 95 °C in a heating block
for 10 min. Tubes were centrifuged at 12,000x g for 6 min to
pellet the filter pieces and the protein extract was collect and
transferred to a fresh capped polypropylene centrifuge tube.
Extraction buffer (20 μl) was added to the pelleted filter paper.
Following vortex and centrifugation, wash was collected and
added to the first protein aliquot.
Determination of total protein concentration in tear and CIC
samples:  All  total  protein  determinations  were  conducted
using  the  DC  Protein  Assay  Kit®  (BioRad),  following
manufacture’s instructions. For samples that contained SDS,
20 µl of Reagent S was added to each ml of Reagent A. Five
µl each of eye wash or impression cytology extract was added
to 5 µl of Milli-Q water and the final 10 µl was divided equally
between two microplate wells to allow assay in duplicate.
Absorbances were read at 750 nm on a Multiskan Microplate
Spectrophotometer (Thermo Fisher Scientific, Mississauga,
Ontario, Canada).
Electrophoresis and immunoblotting: Samples were thawed
at room temperature and diluted 4:1 with 5X sample buffer
(247 mM Tris-HCl, pH 8.6, 2% SDS [w/v], 50 mM DTT, 1X
Complete™  Protease  Inhibitor  [Roche,  Mannheim,
Germany], 10% glycerol, 0.002% [w/v] Bromophenol blue).
Samples were further diluted with 1X sample buffer to achieve
a final protein concentration of 1 μg/μl. Samples were heated
at 100 °C for 3 min, cooled to room temperature than placed
on ice. MUC16 standard antigen (CA125; 1–60 units/well)
was run on each gel to normalize data and facilitate semi-
quantitation of samples, through linear regression analysis.
Ten µg/lane of eye wash protein and 5 µg/lane of CIC total
protein was loaded per lane. Following separation, protein
was  transferred  to  nitrocellulose  membranes  via  vacuum
transfer with 4X SSC buffer for 2 h. Membranes were fixed
by heating at 70 °C for 30 min. Membranes were air dried for
12 h then blocked in PBS + 0.05% Tween-20 (=PBS-T) +
0.1%  BSA  +  10%  NAP  (NAP-Blocker;  G  Biosciences,
Maryland Heights, MD), for 1 h at room temperature on an
orbital shaker. Following three washes with PBS-T, blots
were  incubated  overnight  in  mouse  monoclonal  antibody
clone OC125, (1: 250) in PBS-T and 0.1% BSA + 10% NAP
at 4 °C. After rinsing in PBS-T, blots were incubated with the
secondary antibody (1:5,000) in PBS-T + 0.1% BSA + 10%
NAP for 1 h at room temperature. Blots were developed with
ECL® (BioRad) and chemiluminescent signals were captured
by  Storm840®  Imaging  (Molecular  Dynamics,  Sunnyvale
CA). The amount of MUC16 in each sample and standard
were  quantified  by  image  analysis  software  (ImageQuant
5.1®;  Molecular  Dynamics).  Known  amounts  of  CA125
standard were used to generate standard curves and using the
line-of-best-fit from the standard curve, the relative amount
of mucin in the samples was interpolated from the graph. It
should  be  noted  that  samples  often  produced  multiple
chemiluminescent signals of varying molecular weights. For
quantitation, only signals above 300 kDa for MUC16 were
used.
RNA isolation from CIC samples and reverse transcription:
Tubes containing 1 ml of RLT® buffer (Qiagen) and two
impression cytology samples collected as described above
were allowed to thaw at room temperature then vortexed for
30 s. Membranes were removed using a 21 guage needle and
samples were vortexed again and then passed through a 21
gauge needle for 10 times. Extraction of total RNA proceeded
according to manufacturer’s directions (RNeasy® Minikit;
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The final isolation step was conducted with 40 µl of RNase
free water. Following a 1 min centrifuge step (8,000x g), flow-
through (total RNA) was collected and stored at −80 °C.
RNA quantity and quality were assessed by measuring
the optical density using a Beckman DU530 Life Science UV/
Visible Spectrophotometer at 260 nm and 280 nm. DNA was
synthesized from 8 µl of RNA sample using random hexamer
primers with Superscript™ III First-Strand Synthesis System
for  RT–PCR  (Invitrogen,  Carlsbad,  CA)  according  to  the
manufacturer’s instruction.
Real time-qPCR: Relative expression of genes of interest was
performed  in  multiplex  PCR  reactions  containing  target
(MUC16) and endogenous control (GAPDH) oligonucleotide
primers in the presence of gene-specific dye-labeled Taqman
probes (Table 1). Two microliters of cDNA was used for
amplification in a 50 µl PCR reaction containing target (300
nM)  and  endogenous  control  (100  nM)  oligonucleotide
primers, control and target Taqman probes (100 nM), and
Taqman® Universal PCR Master Mix (Applied Biosystems,
Foster City, CA). Duplicate samples were used for analysis in
a  7500  Real  Time  PCR  System  (Applied  Biosystems).
Conditions used for amplification were as follows: 50 °C for
2 min, followed by an initial 10 min denaturing step at 95 °C.
This was followed by 40 cycles of denaturing at 95 °C for 30
s, annealing at 60 °C for 30 s, and extension at 72 °C for 45 s.
Normalized reporter dye fluorescence (Rn) data was collected
during the extension step at each cycle.
Collected data was analyzed and fold-expression changes
were  calculated  using  the  comparative  method  (2-ΔΔCT)  of
relative  quantification  by  SDS  software  (v1.3.1;  Applied
Biosystems). A sample containing 0.25 pg of plasmid DNA
with cloned target and endogenous fragments was used as a
calibrator sample for each gene.
Data  analysis:  Statistical  analysis  was  performed  using
Statistica Ver7.1 (StatSoft Inc., Tulsa, OK) and Microsoft
Excel™  XLfit©  software.  Graphs  were  plotted  using
Statistica  Ver7.1.  All  data  are  reported  as  mean±standard
deviation.  Statistical  differences  between  groups  for
biomarker data were identified by using one-way ANOVA,
and when necessary, Dunnett’s comparison of means and by
Tukey’s test. Significance was identified at p<0.05 (α=0.05).
RESULTS
Demographics and tear flow measurements: A total of 76
subjects  were  enrolled  into  this  study  and  the  subject
demographics are displayed in Table 2. The mean age of the
SS group was found to be statistically higher than the NDE
group  (p=0.024),  but  not  different  from  the  KCS  group
(p>0.05). Mean Schirmer I scores from both eyes collected
without  anesthesia  for  five  min  revealed  a  significantly
reduced (p<0.0001) tear flow in both SS (5.12±5.96 mm) and
KCS  subjects  (7.84±7.35  mm),  relative  to  NDE
(23.83±7.85 mm). There was no difference in mean Schirmer
I scores between the KCS and SS groups (p=0.19).
MUC16 results: Five of the 25 SS subjects did not supply
sufficient  tear  samples  for  analysis  of  soluble  MUC16,
limiting this analysis to 20 of the 25 subjects. Representative
data are displayed in Figure 1. All samples that were analyzed
displayed quantifiable amounts of soluble MUC16, although
significant inter-sample variation was observed both in terms
of migration pattern of the MUC16 signal on western blots
(Figure 1A) and total amount of MUC16 (Figure 2A). Mean
data showed that the SS group demonstrated significantly
higher concentrations of soluble MUC16 compared to both
KCS  (7.28±3.97  versus  3.35±4.54;  p=0.004)  and  NDE
(7.28±3.97 versus 1.61±1.22; p<0.0001) groups (Figure 2B).
The  SS  group  also  demonstrated  a  significantly  higher
concentration  of  MUC16  mRNA  compared  to  both  KCS
(4.66±5.06 versus 1.84±2.26; p=0.01) and NDE (4.66±5.06
versus 1.52±1.04; p=0.003) groups (Figure 3). No differences
in the concentrations of soluble MUC16 and MUC16 mRNA
were found between the KCS and NDE groups (p>0.05). A
weak (r2=0.13), but significant correlation was found between
TABLE 1. SEQUENCE DATA FOR GENE AMPLIFICATION IN REAL TIME RT–PCR.
Gene Forward primer Reverse primer Taqman probe
MUC16 ACCCAGCTGCAGAACTTCA GGTAGTAGCCTGGGCACTGT 6FAM-GCGGAAGAAGGAAGGAGAAT
GAPDH GAAGGTGAAGGTCGGAGTCA GACAAGCTTCCCGTTCTGAG VIC-CAATGACCCCTTCATTGACC
TABLE 2. SUMMARY OF DEMOGRAPHIC INFORMATION FOR STUDY GROUPS.
Group Mean age
(years)
Number of female
subjects
Number of male
subjects
Total
subjects
NDE 52.4±11.4 24 2 26
KCS 59.3±9.1 21 4 25
Sjogren’s syndrome 60±11.8* 21 4 25
The asterisk denotes significantly greater compared to control group (p=0.024).
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no difference between membrane bound MUC16 was found
between any groups (p>0.05; Figure 4).
A single significant correlation was found between mean
Schirmer  values  compared  with  any  measure  of  MUC16
expression; that being soluble MUC16 concentration in the
combined KCS and NDE groups (Table 3).
DISCUSSION
The  results  of  this  study  demonstrate  that  subjects  with
confirmed Sjogren’s Syndrome display a significant increase
in MUC16 expression, as the concentrations of both MUC16
soluble protein and mRNA were found to be higher than those
Figure 1. Western blot and regression analysis for soluble MUC16
quantification. A: An example of a soluble MUC16 western blot from
tear  samples  derived  from  17  subjects.  Lanes  1–7  are  MUC16
standard  antigen  (CA125)  Units  (based  on  radio-immunoassay
calibration from the vendor); (Lane 1=60, Lane 2=40, Lane 3=20,
Lane 4=10, Lane 5=5, Lane 6=3, Lane 7=1 U); Lanes 8 - 24 are tear
samples. B: A regression curve was created by graphing applied
concentration of CA125 standard against the optical density of the
resulting band immunoreactivity. Total MUC16 concentration was
quantified by extrapolation from this curve using all signal above
300 kDa.
of aqueous deficient dry eye subjects (KCS) and subjects with
no dry eye disease (NDE). There were no differences found
Figure  2.  Soluble  MUC16  expression  as  quantified  by  western
blotting. Data expressed as scatter graph of individual data points
(A) and mean data (B). Protein samples collected via eye wash and
MUC16 data expressed in Units as calculated from extrapolation
from a standard curve titration of CA125. The asterisk indicates
significantly different compared to the NDE group while the sharp
(hash mark) indicates significantly different compared to the KCS
group.
TABLE 3. SLOPE AND CORRELATION DATA SUMMARY FOR COMPARISON OF MUC16 EXPRESSION DATA WITH MEAN SCHIRMER
SCORES.
Subject group Soluble MUC16 versus
Schirmer score
Membrane bound MUC16 versus
Schirmer score
MUC16 mRNA versus
Schirmer score
Sjogren’s data                  y=0.02x + 7.15
r2=0.001; p=0.87                            r2=0.02; p=0.46
y=0.22x + 7.73                               y=0.05x + 4.47
r2=0.004; p=0.77
KCS and NDE data             y=-0.1x + 4.04
r2=0.09; p=0.03                             r2=0.01; p=0.47
y=-0.04x + 7.9                                y=0.004x + 1.6
r2=0.0005; p=0.88
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any of the groups and no difference in any form of MUC16
found  between  the  KCS  and  NDE  groups.  Lastly,  no
correlation between tear flow and MUC16 expression was
found in any group.
The numbers of subjects in this pilot study were small.
Not all SS subjects (5/25) were able to provide sufficient
material for full biochemical analysis. Specifically, total tear
protein collected in the eye wash was insufficient, either due
to very low protein concentration of the tears or low recovery
volume. It is our experience that on very dry eyes, a large
fraction of the applied saline is absorbed by the ocular surface.
Thus, given the potential relevance of our findings, further
investigation of these MUC16 in larger groups is warranted.
We note that age may have been a factor in our results.
The mean age of the two dry-eyed populations was greater
compared to the control group, with significance reached in
the  SS  group.  We  cannot  totally  rule  out  that  this  age
difference may have influenced our findings, as the literature
does suggest that tear volume, production stability and/or
quality is reduced in the older population [32,33]. It is not
known how mucin changes with age on the ocular surface.
However, in our study, there was no significant age difference
between the KCS and SS groups that did show differences.
This group of primary Sjogren’s Syndrome patients was
well  defined,  as  the  diagnosis  was  confirmed  by  the
American-European consensus criterion of 2002 [31]. Our
KCS group had Schirmer test confirmed reduced aqueous
secretions and thus we were able to compare the two well
Figure 3. Summary of MUC16 mRNA expression as quantified by
qPCR. RNA isolated from conjunctival epithelial cells collected via
impression cytology. The asterisk indicates significantly different
compared to the NDE group while the sharp (hash mark) indicates
significantly different compared to the KCS group.
defined aqueous deficient groups as stated in the DEWS 2007
definition of dry eye [28].
Others have explored transmembrane mucin expression
in SS and dry eye disease. Data reported by Spurr-Michaud et
al. [23] describing the presence of MUC16 in the tear film is
confirmed by our results. That MUC16 is one of the trans-
membrane mucins of the surface conjunctival epithelium was
determined by Argueso et al. [9] and its presence within the
conjunctival  epithelium  in  both  protein  and  mRNA  is
confirmed  with  this  study.  There  is,  however,  very  little
additional work on MUC16 in SS. Data on other membrane
bound mucins has suggested that the expression of mucosal
epithelial membrane mucin (as detected by an uncharacterized
antibody referred to as AMEM2), is reduced in SS and non-
SS dry eyed subjects compared to controls [34]. At the genetic
level, a specific splice-variant of MUC1 may be reduced in
dry eyed subjects [35], although others authors have failed to
find  differences  in  MUC1  or  MUC4  expression  between
controls and SS subjects [29].
Our finding of excess MUC16 on the SS ocular surface,
was particularly interesting to the clinical author (B.C.) who
has long observed that excess ocular mucus is a common
clinical finding in SS patients. The sole reference to excess
mucus in SS that we have noted is that of “mucous aggregates”
adherent to the conjunctival and corneal epithelia in a paper
by Pflugfelder et al. [36] in 1990. To our knowledge, this is
the first report of an increase in MUC16 in the tear film of SS
subjects. The authors also understand that the literature does
not characterize SS as a disease of excess mucous production.
In fact, most other papers have suggested that dry eye disease
is a disease of reduced mucous production and secretion [34,
Figure 4. Summary of membrane bound MUC16 as quantified by
western blotting. Protein samples collected via impression cytology.
MUC16 data expressed in Units as calculated from extrapolation
from a standard curve made from titration of CA125.
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shown to be reduced in SS tears and conjunctival cells [29].
Alterations in the distribution of conjunctival epithelial
MUC16 has been noted in dry eye disease. Danjo et al. [30],
using  immunolocalization,  noted  that  superficial  temporal
conjunctival epithelial cells did not bind the H185 antibody
(MUC16) in non-SS dry eye as well as in normal subjects. Our
western blot analysis failed to support these findings. The
H185 epitope has been established as MUC16, however, we
cannot  rule  out  that  different  detection  probes  may  have
influenced these results and that the identification of MUC16
may  be  influenced  by  the  level  of  glycosylation.  That
differential glycosylation of MUC16 may be a relevant area
of study is demonstrated by the significant heterogeneity of
signal  migration  evidenced  in  western  blots.  Whether
differential glycosylation affects antibody recognition and/or
the function properties of the MUC16 protein is not known
currently.
The  selection  of  dry-eyed  subjects  is  an  important
variable in comparing these studies. In part I of Danjo’s [30]
study, when differences between dry eyes and normals were
studied, subjects were chosen by dry eye symptoms and the
presence of rose bengal or fluorescein staining of the ocular
surface, in the absence of autoimmune disease. As Schirmer
testing was not part of this group’s inclusion criteria, true
aqueous deficiency was not established. KCS subjects in the
present study were enrolled based on the presence of at least
moderate dry eye symptoms and a Schirmer score of less than
or equal to 10 mm. Another notable difference is that staining
was not an inclusion criterion in our study. Such differences
in inclusion criteria make comparisons between published
studies somewhat difficult.
Which epithelial cells were used for characterization is
also a relevant factor. In this study, impression cytology was
performed on both temporal and superior bulbar conjunctival
areas and the samples were pooled. Danjo et al. [30], in part I
of their study, used cells from the temporal conjunctiva in the
dry eye group and a combination of inferior and temporal
conjunctiva  from  the  normal  controls.  Clinically,  staining
patterns of the conjunctiva are quite different and, as such, it
is likely that differential expression of various mucin species
may be a function of which cells were analyzed. Comparing
mucin expression in exposed and non exposed conjunctival
cells would be an important contribution to the literature.
Alterations in membrane MUC16 has been studied in
relationship  to  conjunctival  staining.  Dry  eye  patients,
particularly those with Sjogren’s syndrome, present clinically
with rose bengal staining of the conjunctiva and cornea [31].
Initially  rose  bengal  was  thought  to  stain  cells  that  were
desquamated or dead [39-42]. More recently, the dysfunction
of  mucins  has  been  implicated.  Danjo  et  al.  [30]  studied
aqueous deficient but not SS dry eyed subjects, who had
Schirmer scores of less than or equal to 5 mm in 5 min and
staining by rose bengal or fluorescein, in part II of their study .
They found a significant correlation between staining scores
of the temporal conjunctiva and an altered H185 (MUC16)
binding pattern. Two studies used a human corneal-limbal
epithelial  cell  line  (HCLE)  to  demonstrate  that  MUC16
surface protein protects against rose bengal invasion [22,26].
Others have reported a positive correlation between decreased
transmembrane mucin (not identified) and higher rose bengal
staining in aqueous deficient dry eye [34]. Although we did
not stain the ocular surface of the subjects at the time of their
visit for tear and cell collection in this study, our results
suggest that staining scores, at least in SS patients, would not
correlate with a reduction in membrane MUC16, as we found
no differences in membrane bound MUC16 expression in any
of our subject groups.
The observation of excess ocular mucus in SS patients
and the results of this study that show excess MUC16 in the
tear film of SS subjects, allowed us to speculate on the possible
mechanisms of such mucin production. It appears that there
is  an  active  upregulation  of  mucin  production  in  our  SS
subjects, as determined by increased mRNA, followed by
excess  shedding  of  this  mucin  into  the  tear  film.  Mucin
production in humans is an ancient defense mechanism [43]
and  non-ocular  mucous  membranes,  such  as  those  of  the
airways,  demonstrate  excess  mucous  production  under
adverse conditions in dogs, rats, and humans [44-46]. The
ocular  surface  performs  compensatory  mucin  related
activities in other autoimmune states such as ocular cicatricial
pemphigoid (OCP). As the OCP ocular surface moves toward
keratinisation, there is increased expression of the family of
glycosyltransferases that act at the initial stages of mucin
glycosylation [47]. That these findings were found in the early
stages  of  the  keratinization  process  suggests  that  ocular
surface  cells  can  participate  in  compensatory  attempts  to
synthesize more mucin to maintain a wet surface phenotype.
Since our results demonstrated no correlation between tear
flow  and  MUC16  concentration,  we  believe  that  it  is  the
unique nature of autoimmune related dry eye that influences
the stimulus for MUC16 expression. Perhaps this is a result
of a signaling mechanism peculiar to SS, that functions to
maintain a more “healthy” ocular surface in the absence of
aqueous tears.
Another factor that could increase the concentration of
MUC16 on the SS ocular surface is the change in flushing and
clearing mechanisms that occur with extreme dryness. Berry
et al. [48] suggest that in dry eye, tear mucins may form an
irreversible complex with other surface components, which
prevents normal removal.
In  summary,  we  quantified  the  expression  of  ocular
surface MUC16 in Sjogren’s subjects and compared them
with  non-Sjogren’s  dry-eyed  subjects  and  non-dry  eyed
controls.  We  found  that  Sjogren’s  subjects  express
significantly elevated concentrations of both soluble MUC16
Molecular Vision 2008; 14:2547-2555 <http://www.molvis.org/molvis/v14/a293> © 2008 Molecular Vision
2553and MUC16 mRNA compared to both KCS and NDE groups.
No differences were found in MUC16 expression between the
KCS  and  NDE  subjects.  All  three  groups  had  similar
concentrations of membrane bound MUC16. No correlation
was found between tear flow and MUC16 expression. We
propose  that  conjunctival  cells  in  Sjogren’s  syndrome
increase  their  production  of  MUC16  as  a  compensatory
mechanism to maintain their healthy phenotype.
REFERENCES
1. Dilly PN. Structure and function of the tear film. Adv Exp Med
Biol 1994; 350:239-47. [PMID: 8030483]
2. Pflugfelder  SC,  Solomon  A,  Stern  ME.  The  diagnosis  and
management of dry eye: a twenty-five-year review. Cornea
2000; 19:644-9. [PMID: 11009316]
3. Dilly PN. Contribution of the epithelium to the stability of the
tear  film.  Trans  Ophthalmol  Soc  U  K  1985;  104:381-9.
[PMID: 3898473]
5. Holly FJ. Formation and rupture of the tear film. Exp Eye Res
1973; 15:515-25. [PMID: 4712544]
6. Pflugfelder SC, Liu ZG, Munroy D, Li DQ, Carvajal ME, Price-
Schiavi SA, Idris N, Solomon A, Perez A, Carraway KL.
Detection of sialomucin complex (MUC4) in human ocular
surface epithelium and tear fluid. Invest Ophthalmol Vis Sci
2000; 41:1316-26. [PMID: 10798646]
7. Gipson IK. Distribution of mucins at the ocular surface. Exp
Eye Res 2004; 78:379-88. [PMID: 15106916]
8. McKenzie RW, Jumblatt JE, Jumblatt MM. Quantification of
MUC2  and  MUC5AC  transcripts  in  human  conjunctiva.
Invest  Ophthalmol  Vis  Sci  2000;  41:703-8.  [PMID:
10711684]
9. Argueso P, Spurr-Michaud S, Russo CL, Tisdale AS, Gipson
IK. MUC16 mucin is expressed by the human ocular surface
epithelia and carries the H 185 carbohydrate epitope. Invest
Ophthalmol Vis Sci 2003; 44:2487-95. [PMID: 12766047]
10. Inatomi T, Spurr-Michaud S, Tisdale AS, Zhan Q, Feldman ST,
Gipson IK. Expression of secretory mucin genes by human
conjunctival epithelium. Invest Ophthalmol Vis Sci 1996;
37:1684-92. [PMID: 8675412]
11. Gendler  SJ,  Spicer  AP.  Epithelial  mucin  genes.  Annu  Rev
Physiol 1995; 57:607-34. [PMID: 7778880]
12. Shankar V, Pichan P, Eddy RL Jr, Tonk V, Nowak N, Sait SN,
Shows TB, Schultz RE, Gotway G, Elkins RC, Gilmore MS,
Sachdev G. Chromosomal localization of a human mucin
gene (MUC8) and cloning of the cDNA corresponding to the
carboxyl  terminus.  Am  J  Respir  Cell  Mol  Biol  1997;
16:232-41. [PMID: 9070607]
13. Lapensee L, Paquette Y, Bleau G. Allelic polymorphism and
chromosomal  localization  of  the  human  oviductin  gene
(MUC9). Fertil Steril 1997; 68:702-8. [PMID: 9341614]
14. Williams SJ, McGuckin MA, Gotly DC, Eyre HJ, Sutherland
GR, Antalis TM. Two novel mucin genes down-regulated in
colorectal cancer identified by different display. Cancer Res
1999; 59:4083-9. [PMID: 10463611]
15. Williams SJ, Wreschner DH, Tran M, Eyre HJ, Sutherland GR,
McGuckin MA. MUC13, a novel human cell surface mucin
expressed by epithelial and hemopoietic cells. J Biol Chem
2001; 276:18327-36. [PMID: 11278439]
16. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian
cancer antigen: identification as a new mucin (MUC16). J
Biol Chem 2001; 276:27371-5. [PMID: 11369781]
17. Pallesen  LT,  Berglund  L,  Rasmussen  LK,  Petersen  TE,
Rasmussen JT. Isolation and characterization of MUC15, a
novel cell membrane-associated mucin. Eur J Biochem 2002;
269:2755-63. [PMID: 12047385]
18. Gum JR, Crawley SC, Hicks JW, Azymkowski DE, Kim YS.
MUC17,  a  novel  membrane-associated  tethered  mucin.
Biochem Biophys Res Commun 2002; 291:466-75. [PMID:
11855812]
19. Higuchi T, Orita T, Nakanishi S, Katsuya K, Wanatanabe H,
Yamasaki Y, Waga I, Nanayama T, Yamamoto Y, Munger
W,  Sun  HW,  Falk  RJ,  Jennette  JC,  Alcorta  DA,  Li  H,
Yamamoto  T,  Saito  Y,  Nakamura  M.  Molecular  cloning,
genomic  structure,  and  expression  analysis  of  MUC20,  a
novel protein, up-regulated in injured kidney. J Biol Chem
2004; 279:1968-79. [PMID: 14565953]
20. Inatomi T, Spurr-Michaud S, Tisdale AS, Gipson IK. Human
corneal  and  conjunctival  epithelia  express  MUC1  mucin.
Invest  Ophthalmol  Vis  Sci  1995;  36:1818-27.  [PMID:
7635656]
21. Gipson IK. Distribution of mucins at the ocular surface. Exp
Eye Res 2004; 78:379-88. [PMID: 15106916]
22. Blalock  TD,  Spurr-Michaud  S,  Tisdale  AS,  Heimer  SR,
Gilmore MS, Ramesh V, Gipson IK. Functions of MUC16 in
corneal  epithelial  cells.  Invest  Ophthalmol  Vis  Sci  2007;
48:4509-18. [PMID: 17898272]
23. Spurr-Michaud S, Argueso P, Gipson I. Assay of mucins in
human tear fluid. Exp Eye Res 2007; 84:939-50. [PMID:
17399701]
24. Gendler  SJ.  MUC1,  the  renaissance  molecule.  J  Mammary
Gland Biol Neoplasia 2001; 6:339-53. [PMID: 11547902]
25. Hori Y, Spurr-Michaud S, Russo CL, Argueso P, Gipson IK.
Differential regulation of membrane-associated mucins in the
human ocular surface epithelium. Invest Ophthalmol Vis Sci
2004; 45:114-22. [PMID: 14691162]
26. Argueso  P,  Tisdale  AS,  Spurr-Michaud  S,  Sumiyoshi  M,
Gipson IK. Mucin characteristics of human corneal-limbal
epithelial cells that exclude the rose bengal anionic dye. Invest
Ophthalmol Vis Sci 2006; 47:113-9. [PMID: 16384952]
27. Hori Y, Argueso P, Spurr-Michaud S, Gipson IK. Mucins and
contact  lens  wear.  Cornea  2006;  25:176-81.  [PMID:
16371777]
28. Lemp  MA,  Baudouin  C,  Baum  J,  Dogru  M,  Foulks  GN,
Kinoshita  S.  The  definition  and  classification  of  dry  eye
disease:  Report  of  the  Definition  and  Classification
Subcommittee of the international Dry Eye Workshop (2007).
Ocul Surf 2007; 5:75-92. [PMID: 17508116]
29. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana
MR, Gipson IK. Decreased levels of the goblet cell mucin
MUC5AC in tears of patients with Sjogren's syndrome. Invest
Ophthalmol Vis Sci 2002; 43:1004-11. [PMID: 11923240]
30. Danjo Y, Watanabe H, Tisdale AS, George M, Tsumura T,
Abelson  MB,  Gipson  IK.  Alteration  of  mucin  in  human
Molecular Vision 2008; 14:2547-2555 <http://www.molvis.org/molvis/v14/a293> © 2008 Molecular Vision
2554
4. Gipson I, Inatomi T. Cellular origins of mucins of the ocular
surface tear film. In: Sullivan D, Dartt D, Meneray M, editors.
Lacrimal Gland, Tear Film and Dry Eye Syndromes 2. New
York: Plenum Press; 1998. p. 221–227.conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci
1998; 39:2602-9. [PMID: 9856770]
31. Vitali  C,  Bombardieri  S,  Jonsson  R,  Moutsopoulos  H,
Alexander EL, Carsons SE, Daniels TE, Fox PC, Flox RI,
Kassan  SS,  Pillemer  SR,  Talal  N,  Weisman  MH.
Classification  criteria  for  Sjogren's  syndrome:  a  revised
version of the European criteria proposed by the American-
European  Consensus  Group.  Ann  Rheum  Dis  2002;
61:554-8. [PMID: 12006334]
32. Mathers WD, Lane JA, Zimmerman MB. Tear film changes
associated  with  normal  aging.  Cornea  1996;  15:229-34.
[PMID: 8713923]
33. Patel S, Farrell J. Age related changes in pre-corneal tear film
stability. Optom Vis Sci 1989; 66:175-8. [PMID: 2717147]
34. Pflugfelder SC, Tseng SCG, Yoshino K, Monroy D, Felix C,
Reis  BL.  Correlation  of  goblet  cell  density  and  mucosal
epithelial  mucin  expression  with  rose  bengal  staining  in
patients  with  ocular  irritation.  Ophthalmology  1997;
104:223-35. [PMID: 9052626]
35. Imbert Y, Darling DS, Jumblatt MM, Foulks GN, Couzin EG,
Steele PS, Young WW Jr. MUC1 splice variants in human
ocular surface tissues: possible differences between dry eye
patients  and  normal  controls.  Exp  Eye  Res  2006;
83:493-501. [PMID: 16631167]
36. Pflugfelder SC, Huang AJ, Feuer WJ, Chuchovski PT, Pereira
IC, Tseng SC. Conjunctival cytologic features of primary
Sjogren's  syndrome.  Ophthalmology  1990;  97:985-91.
[PMID: 1698273]
37. Nelson JD, Wright JC. Conjunctival goblet cell densities in
ocular  surface  disease.  Arch  Ophthalmol  1984;
102:1049-51. [PMID: 6378156]
38. Zhao H, Jumblatt JE, Wood TO, Jumblatt MM. Quantification
of  MUC5AC  protein  in  human  tears.  Cornea  2001;
20:873-7. [PMID: 11685069]
39. Passmore J, King JJ. Vital staining of conjunctiva and cornea:
review of literature and critical study of certain dyes. Arch
Ophthalmol 1954; 53:568-74.
40. Norn MS. Vital staining of the cornea and conjunctiva. Acta
Ophthalmol (Copenh) 1973; 51:483-91. [PMID: 4128796]
41. Kim J, Foulks G. Evaluation of the effect of lissamine green and
rose bengal on human corneal epithelial cells. Cornea 1999;
18:328-32. [PMID: 10336037]
42. Feenstra RP, Tseng SC. What is actually stained by rose bengal?
Arch Ophthalmol 1992; 110:984-93. [PMID: 1637285]
43. Basbaum  C,  Lemjabbar  H,  Longphre  M,  Li  D,  Gensch  E,
McNamara  N.  Control  of  mucin  transcription  by  diverse
injury-induced signalling pathways. Am J Respir Crit Care
Med 1999; 160:S44-8. [PMID: 10556169]
44. Marom Z, Shelhamer JH, Sun F, Kaliner M. Human airway
mono-hydroxyeicosatetraenoic  acid  generation  and  mucus
release. J Clin Invest 1983; 72:122-7. [PMID: 6308043]
45. Johnson  HG,  McNee  ML,  Sunn  FF.  15-
hydroxyeicosatetraenoic  acid  is  a  potent  inflammatory
mediator and agonist of canine tracheal mucus secretion. Am
Rev Respir Dis 1985; 131:917-22. [PMID: 3923884]
46. Yanni JM, Foxwell MH, Whitman LL, Smith WL, Nolan JC.
Effect  of  intravenously  administered  lypoxygenase
metabolites on rat tracheal mucous gel layer thickness. Int
Arch  Allergy  Appl  Immunol  1989;  90:307-9.  [PMID:
2556352]
47. Argüeso P, Tisdale A, Mandel U, Letko E, Foster CS, Gipson
IK.  The  cell-layer-and  cell-type-specific  distribution  of
GalNAc-transferases in the ocular surface epithelia is altered
in  keratinization.  Invest  Ophthalmol  Vis  Sci  2003;
44:86-92. [PMID: 12506059]
48. Berry M, Ellingham R, Corfield A. Human preocular mucins
reflect changes in surface physiology. Br J Ophthalmol 2004;
88:377-83. [PMID: 14977773]
Molecular Vision 2008; 14:2547-2555 <http://www.molvis.org/molvis/v14/a293> © 2008 Molecular Vision
The print version of this article was created on 24 December 2008. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
2555